Minori Koshiji
Overview
Explore the profile of Minori Koshiji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
7106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doi T, Piha-Paul S, Jalal S, Saraf S, Lunceford J, Koshiji M, et al.
J Clin Oncol
. 2017 Nov;
36(1):61-67.
PMID: 29116900
Purpose The anti-programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)-positive advanced solid tumors. Results from the esophageal carcinoma...
2.
Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S, et al.
Lancet Oncol
. 2016 May;
17(6):717-726.
PMID: 27157491
Background: Expression of PD-L1 has been shown to be upregulated in some patients with gastric cancer. As part of the phase 1b KEYNOTE-012 study, we aimed to assess the safety...
3.
Wu F, Rom W, Koshiji M, Mo Y, Hosomi Y, Tchou-Wong K
J Environ Pathol Toxicol Oncol
. 2015 Sep;
34(3):213-25.
PMID: 26349604
We examined the effects of GLI1 expression in PW mouse embryo fibroblasts and H441 lung carcinoma cells. Ectopic expression of GLI1 in PW cells induced anchorage-independent growth and increased resistance...
4.
Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A, et al.
N Engl J Med
. 2015 Jun;
372(26):2509-20.
PMID: 26028255
Background: Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to...
5.
Fuchs C, Tomasek J, Yong C, Dumitru F, Passalacqua R, Goswami C, et al.
Lancet
. 2013 Oct;
383(9911):31-39.
PMID: 24094768
Background: Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether ramucirumab, a...
6.
Fukutomi A, Furuse J, Okusaka T, Miyazaki M, Taketsuna M, Koshiji M, et al.
HPB (Oxford)
. 2012 Mar;
14(4):221-7.
PMID: 22404259
Background/purpose: Complications from biliary drainage in biliary tract cancer (BTC) may influence the relative dose intensity of chemotherapy or increase adverse events during chemotherapy. BT22 was a randomized phase II...
7.
Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, et al.
Cancer Sci
. 2011 Jan;
102(2):432-8.
PMID: 21205069
Patients with follicular lymphoma (FL), where position 158 of FcγR-IIIa is heterozygous valine/phenylalanine or homozygous phenylalanine (F-carriers), have natural killer cells with lower binding affinity to IgG than valine homozygote...
8.
Furuse J, Okusaka T, Bridgewater J, Taketsuna M, Wasan H, Koshiji M, et al.
Crit Rev Oncol Hematol
. 2010 Nov;
80(1):31-9.
PMID: 21094052
There had been no standard chemotherapy established for advanced biliary tract cancer (BTC) until 2009, when the combination of cisplatin and gemcitabine (GC) was adopted as a first line standard...
9.
Mukohara T, Nagai S, Koshiji M, Yoshizawa K, Minami H
Cancer Sci
. 2010 Aug;
101(10):2193-9.
PMID: 20707806
Enzastaurin is an oral serine/threonine kinase inhibitor that targets the protein kinase C (PKC) and phosphoinositide 3-kinase/AKT pathways to induce apoptosis and suppress proliferation of various cancer cell lines. This...
10.
Tanai C, Yamamoto N, Ohe Y, Takahashi T, Kunitoh H, Murakami H, et al.
J Thorac Oncol
. 2010 May;
5(7):1068-74.
PMID: 20453691
Introduction: Enzastaurin is an oral serine/threonine kinase inhibitor, which suppress signaling through protein kinase C-beta and the phosphatidylinositol 3-kinase/AKT pathway. Preclinical studies suggested synergic antitumor activity of enzastaurin and pemetrexed....